Initial Evaluation on the Safety and Efficacy of Accelerated Hyperfractionated Radiotherapy for Locally Advanced Cervical Cancer: A Pilot Study

We used the accelerated hyperfractionated radiotherapy of locally advanced cervical cancer and assessed the initial treatment efficacy and safety.
This study enrolled three patients. Using a field-infield technique, the whole pelvic region was set as a large irradiated field and received a dose of 35.2-39.6 Gy, whereas small field irradiation targeting only the tumor and parametrium was performed at
9.6-10.8 Gy. We then performed center shield field irradiation of the pelvic lymph node area, which were irradiated at 50 Gy in sum total. Intracavitary radiotherapy was added two to three times. Two patients received chemotherapy. In all patients, treatments
were completed with overall treatment time （OTT） of 37-40 days. All patients were in complete response. Acute adverse events included two cases of grade 3 leukopenia, one case of grade 3 neutropenia.
In conclusion, this treatment was effective and safet with good outcomes, acceptable adverse events, and greatly reduced OTT.